OncoMatch/Clinical Trials/NCT07226427
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Is NCT07226427 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies MEN2501 for platinum-resistant ovarian cancer.
Treatment: MEN2501 — This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NEXT Virginia · Fairfax, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07226427 currently recruiting?
Yes, this trial is currently recruiting patients.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages